Is Processa Pharmaceuticals Stock a Good Investment?
Processa Pharmaceuticals Investment Advice | PCSA |
- Examine Processa Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Processa Pharmaceuticals' leadership team and their track record. Good management can help Processa Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Processa Pharmaceuticals' business and its evolving consumer preferences.
- Compare Processa Pharmaceuticals' performance and market position to its competitors. Analyze how Processa Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Processa Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Processa Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Processa Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Processa Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Processa Pharmaceuticals Stock
Researching Processa Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 1.01. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Processa Pharmaceuticals recorded a loss per share of 4.8. The entity last dividend was issued on the 23rd of December 2019. The firm had 1:20 split on the 22nd of January 2024.
To determine if Processa Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Processa Pharmaceuticals' research are outlined below:
| Processa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Processa Pharmaceuticals may become a speculative penny stock | |
| Processa Pharmaceuticals has high historical volatility and very poor performance | |
| Processa Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (11.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Processa Pharmaceuticals currently holds about 12.06 M in cash with (8.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Processa Pharmaceuticals has a poor financial position based on the latest SEC disclosures |
Processa Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Processa Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Processa Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Processa Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Processa Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-13 | 2023-09-30 | -0.1 | -0.08 | 0.02 | 20 | ||
2022-03-30 | 2021-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2023-03-30 | 2022-12-31 | -0.32 | -0.36 | -0.04 | 12 | ||
2021-05-13 | 2021-03-31 | -0.1 | -0.14 | -0.04 | 40 | ||
2021-08-12 | 2021-06-30 | -0.14 | -0.2 | -0.06 | 42 | ||
2023-05-15 | 2023-03-31 | -0.28 | -0.18 | 0.1 | 35 | ||
2022-08-11 | 2022-06-30 | -0.2 | -0.32 | -0.12 | 60 | ||
2023-08-10 | 2023-06-30 | -0.23 | -0.097 | 0.133 | 57 |
Know Processa Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Processa Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Processa Pharmaceuticals backward and forwards among themselves. Processa Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Processa Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 24.4 K | Geode Capital Management, Llc | 2024-09-30 | 19.7 K | Tower Research Capital Llc | 2024-06-30 | 3 K | Wells Fargo & Co | 2024-06-30 | 154 | Main Street Group Ltd | 2024-06-30 | 100.0 | Hanson Mcclain Inc | 2024-09-30 | 85.0 | Bank Of America Corp | 2024-06-30 | 21.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Absolute Investment Management Llc | 2024-09-30 | 1.0 |
Processa Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.78 M.Market Cap |
|
Processa Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.92) | (2.02) | |
| Return On Capital Employed | (2.27) | (2.38) | |
| Return On Assets | (1.92) | (2.02) | |
| Return On Equity | (2.23) | (2.34) |
Determining Processa Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Processa Pharmaceuticals is a good buy. For example, gross profit margin measures Processa Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Processa Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Processa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Processa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Processa Pharmaceuticals' management manipulating its earnings.
Evaluate Processa Pharmaceuticals' management efficiency
Processa Pharmaceuticals has return on total asset (ROA) of (1.1311) % which means that it has lost $1.1311 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1171) %, meaning that it created substantial loss on money invested by shareholders. Processa Pharmaceuticals' management efficiency ratios could be used to measure how well Processa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -2.02. In addition to that, Return On Capital Employed is expected to decline to -2.38. At present, Processa Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 9.7 M, whereas Non Current Assets Total are forecasted to decline to about 146.4 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.81 | 3.62 | |
| Tangible Book Value Per Share | 3.81 | 4.00 | |
| Enterprise Value Over EBITDA | (0.37) | (0.39) | |
| Price Book Value Ratio | 1.76 | 1.67 | |
| Enterprise Value Multiple | (0.37) | (0.39) | |
| Price Fair Value | 1.76 | 1.67 | |
| Enterprise Value | 30.9 M | 21.9 M |
Leadership at Processa Pharmaceuticals emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 0.597 |
Basic technical analysis of Processa Stock
As of the 1st of December, Processa Pharmaceuticals holds the Variance of 21.46, risk adjusted performance of (0.03), and Coefficient Of Variation of (2,169). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Processa Pharmaceuticals, as well as the relationship between them.Processa Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Processa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Processa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Processa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Processa Pharmaceuticals' Outstanding Corporate Bonds
Processa Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Processa Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Processa bonds can be classified according to their maturity, which is the date when Processa Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| PROCTER GAMBLE 645 Corp BondUS742718BH18 | View | |
| US742718AV11 Corp BondUS742718AV11 | View | |
| PROCTER GAMBLE 55 Corp BondUS742718CB39 | View | |
| PROCTER GAMBLE 555 Corp BondUS742718DF34 | View |
Understand Processa Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Processa Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 3.05 | |||
| Coefficient Of Variation | (2,169) | |||
| Standard Deviation | 4.63 | |||
| Variance | 21.46 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 20.99 | |||
| Value At Risk | (5.34) | |||
| Potential Upside | 7.26 | |||
| Skewness | 1.15 | |||
| Kurtosis | 4.59 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 3.05 | |||
| Coefficient Of Variation | (2,169) | |||
| Standard Deviation | 4.63 | |||
| Variance | 21.46 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 20.99 | |||
| Value At Risk | (5.34) | |||
| Potential Upside | 7.26 | |||
| Skewness | 1.15 | |||
| Kurtosis | 4.59 |
Consider Processa Pharmaceuticals' intraday indicators
Processa Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Processa Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Processa Pharmaceuticals time-series forecasting models is one of many Processa Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Processa Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Processa Stock media impact
Far too much social signal, news, headlines, and media speculation about Processa Pharmaceuticals that are available to investors today. That information is available publicly through Processa media outlets and privately through word of mouth or via Processa internal channels. However, regardless of the origin, that massive amount of Processa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Processa Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Processa Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Processa Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Processa Pharmaceuticals alpha.
Processa Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Processa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Processa Pharmaceuticals Corporate Management
| James Stanker | Chief Officer | Profile | |
| PharmD Bigora | CoFounder Officer | Profile | |
| Russell MBA | Chief Officer | Profile | |
| Steven MD | Senior Research | Profile | |
| Robert Floyd | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Processa Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.